title: Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges.
abstract: The results of this study confirmed that dogs vaccinated subcutaneously with a commercially available multivalent vaccine containing modified-live canine distemper virus, canine adenovirus type 2, canine parvovirus type 2b, and canine parainfluenza virus antigens were protected against sequential experimental challenge 55 to 57 months after initial vaccination given at 7 to 8 weeks of age. All 10 vaccinates were protected against clinical diseases and mortality following parvovirus and infectious canine hepatitis experimental infections. All vaccinates were protected against mortality and 90% against clinical disease following distemper challenge. These data support at least a 4-year duration of immunity for these three "core" fractions in the combination vaccine.
authors.affiliation: Schering-Plough Animal Health, Research and Development, 21401 West Center Road, Elkhorn, NE 68022, USA.
authors.forename: Omar Y
authors.initials: OY
authors.lastname: Abdelmagid
authors.forename: Laurie
authors.initials: L
authors.lastname: Larson
authors.forename: Laurie
authors.initials: L
authors.lastname: Payne
authors.forename: Anna
authors.initials: A
authors.lastname: Tubbs
authors.forename: Terri
authors.initials: T
authors.lastname: Wasmoen
authors.forename: Ronald
authors.initials: R
authors.lastname: Schultz
mesh_terms: D006516:Adenoviruses, Canine / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D004216:Distemper / Q000517:prevention & control; D004217:Distemper Virus, Canine / Q000276:immunology; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D006522:Hepatitis, Infectious Canine / Q000517:prevention & control; D008297:Male; D022241:Parainfluenza Vaccines / Q000008:administration & dosage / Q000276:immunology; D010322:Parvoviridae Infections / Q000517:prevention & control / Q000662:veterinary; D017993:Parvovirus, Canine / Q000276:immunology / Q000472:pathogenicity; D011897:Random Allocation; D013997:Time Factors; D016896:Treatment Outcome; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology; D014774:Virulence; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*
chemical_list: D000914:Antibodies, Viral; D022241:Parainfluenza Vaccines; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D014765:Viral Vaccines